Citations

Institution: Mayo Clinic Clear

Showing 10 of 108104 citations.

Surgical innovation
Nelson, Heidi

British Journal of Surgery | February 21, 2013 | Volume: 100 | Issue: 6 | Pages: 721-723

10.1002/bjs.9093 | PMID 23436716 Get It

A Nobel pursuit
Serial infusions of low-dose ketamine for major depression
Rasmussen, Keith G., Lineberry, Timothy W., Galardy, Christine W., Kung, Simon , Palmer, Brian A. , Ritter, Matthew J. , Schak, Kathryn M. , Sola, Christopher L., Hanson, Allison J, Frye, Mark A. , Lapid, Maria I.

Journal of Psychopharmacology | February 21, 2013 | Volume: 27 | Issue: 5 | Pages: 444-450

10.1177/0269881113478283 | PMID 23428794 Get It

Background: Single infusions of ketamine have been used successfully to achieve improvement in depressed patients. Side effects during the infusions have been common. It is not known whether serial infusions or lower infusion rates result in greater efficacy. Methods: Ten depressed patients were treated with twice weekly ketamine infusions of ketamine 0.5 mg/kg administered over 100 min until either remission was achieved or four infusions were given. Side effects were assessed with the Young Mania Rating Scale (YMRS) and the Brief Psychiatric Rating Scale (BPRS). Patients were followed naturalistically at weekly intervals for four weeks after completion of the infusions. Results: Five of 10 patients achieved remission status. There were no significant increases on the BPRS or YMRS. Two of the remitting patients sustained their improvement throughout the four week follow-up period. Conclusions: Ketamine infusions at a lower rate than previously reported have demonstrated similar efficacy and excellent tolerability and may be more practically available for routine clinical care. Serial ketamine infusions appear to be more effective than a single infusion. Further research to test relapse prevention strategies with continuation ketamine infusions is indicated.
Proton Magnetic Resonance Spectroscopy as a Probe into the Pathophysiology ofAutismSpectrumDisorders (ASD): A Review
Baruth, Joshua , Wall, Christopher A., Patterson, Marc C. , Port, John D. , Port, John D , Patterson, Marc

Autism Research | February 21, 2013 | Volume: 6 | Issue: 2 | Pages: 119-133

10.1002/aur.1273 | PMID 23436782 Get It

Proton magnetic resonance spectroscopy (1H‐MRS) is a safe, noninvasive way of quantifying in vivo biochemical and metabolite concentration levels in individuals withAutismSpectrumDisorders (ASD). Findings to date suggestASDis associated with widespread reduction inN‐acetylaspartate (NAA), creatine plus phosphocreatine (Cr), choline‐containing compounds (Cho),myo‐inositol (mI), and glutamate plus glutamine plus gamma‐Aminobutyric Acid (Glx); however, variable findings, and even substantial increases, are not uncommon depending on the study and/or region‐of‐interest. Widespread reduction ofNAA,Cr,Cho,mI, andGlxinASDlikely reflects impaired neuronal function and/or metabolism related to abnormal neurodevelopmental processes. Future studies should attempt to relate1H‐MRSfindings to histological findings and control for variability in subject age and functioning level; this would assist in evaluating the relationship between1H‐MRSmetabolic levels and neuronal and glial cell densities, as well as neurodevelopmental process associated withASD. Furthermore, more longitudinal1H‐MRSstudies are needed in both control andASDsubjects to attempt to standardize metabolite levels across different developmental periods in well‐defined endophenotypes. This will provide for a standard rubric for which metabolic aberrations (as well as treatment responses) can be measured. With higher magnetic field strengths and spectral‐editing techniques capable of quantifying less‐concentrated metabolites,1H‐MRSwill continue to be an important tool inASDresearch.Autism Res2013, 6: 119–133.© 2013 International Society for Autism Research, Wiley Periodicals, Inc.
Comparison between three‐dimensional angiographic reconstruction and intravascular ultrasound: Imaging of the left main coronary artery
Spoon, Daniel B., Rubinshtein, Ronen, Psaltis, Peter J. , Sandhu, Gupreet S., Lennon, Ryan J. , Rihal, Charanjit S. , Rihal, Charanjit S. , Lerman, Amir

Catheterization and Cardiovascular Interventions | February 21, 2013 | Volume: 81 | Issue: 7 | Pages: 1156-1161

10.1002/ccd.24733 | PMID 23436576 Get It

ObjectivesThe purpose of this study was to evaluate the left main (LM) coronary artery anatomy using three‐dimensional (3D) quantitative coronary angiography (QCA) software as compared to intravascular ultrasound (IVUS).BackgroundPercutaneous intervention of the LM coronary artery is becoming more common in selected patients with LM coronary artery disease (CAD). Quantification of LM CAD by conventional angiography can be difficult. IVUS is considered the gold standard to evaluate LM anatomy and severity of CAD but entails additional steps, catheters, and expertise. Our objective was to compare a novel quantitative angiographic analysis system with IVUS for LM anatomy.MethodsFifty five patients underwent both coronary angiography and IVUS of the LM. LM measurements were analyzed with 3D QCA (IC‐PRO, Paieon, Israel) software using IVUS as the reference standard. The measurements included proximal, middle, distal minimal luminal diameter (MLD) and area. Additionally, lesion MLD, minimal luminal area were recorded by both systems. Bland–Altman plots were used to investigate agreement between the two imaging systems.ResultsOf the 55 patients in our cohort, average age was 66 ± 11 years (25% female). By Bland‐Altman analysis there was very good agreement between 3D QCA and IVUS for measures of MLD and minimal lumen area (MLA). However, there was poor concordance in the estimation of plaque burden between the two methods.ConclusionsOur data demonstrate that 3D QCA software has fair agreement when compared with IVUS for imaging of LM MLD and MLA. These results suggest that 3D QCA could potentially be helpful to guide intervention of the LM. © 2012 Wiley Periodicals, Inc.
Tired of Being Tired
Carey, Elizabeth J. , Mayer, Anita P. , Files, Julia A.

Journal of Women's Health | February 21, 2013 | Volume: 22 | Issue: 3 | Pages: 289-290

10.1089/jwh.2012.4225 | PMID 23428285 Get It

Factors Associated with Surgical Decision Making in Women with Early-Stage Breast Cancer: A Literature Review
Bride, Maire Brid Mac, Neal, Lonzetta, Dilaveri, Christina A. , Sandhu, Nicole P. , Ghosh, Karthik, Wahner‐Roedler, Dietlind L. , Hieken, Tina J.

Journal of Women's Health | February 21, 2013 | Volume: 22 | Issue: 3 | Pages: 236-242

10.1089/jwh.2012.3969 | PMID 23428286 Get It

Background: Current recommendations for surgical management of early-stage breast cancer include breast-conserving surgery with postoperative irradiation. However, studies show that mastectomy is still being used by women with early-stage breast cancer. Methods: Review of the medical literature published between 2000 and 2010 to determine the factors associated with the decision of patients for surgical treatment in early-stage breast cancer. Results: The following patient characteristics affect the surgical decision-making process in early-stage breast cancer: age, socioeconomic factors, geographic area in which the patient lives, proximity to a radiation therapy center, testing for BRCA gene, breast imaging, and decision aids. Conclusions: Of increasing importance in the decision making about treatment of women with early-stage breast cancer are the woman's perception of having a surgical choice and the influence of that choice on postoperative quality of life.
Utility of baseline positron emission tomography with computed tomography for predicting endoscopic resectability and survival outcomes in patients with early esophageal adenocarcinoma
Sun, Gang , Tian, Jianmin, Gorospe, Emmanuel C., Johnson, Geoffrey B. , Lutzke, Lori S., Leggett, Cadman L. , Iyer, Prasad G. , Wang, Kenneth K, Johnson, Geoffrey B. , Hunt, Christopher H. , Johnson, Geoffrey B , Johnson, Geoffrey B , Leggett, Cadman L

Journal of Gastroenterology and Hepatology | February 21, 2013 | Volume: 28 | Issue: 6 | Pages: 975-981

10.1111/jgh.12148 | PMID 23425230 Get It

AbstractBackground and AimsPositron emission tomography with computed tomography (PET/CT) has been used to detect metastasis in the diagnosis of esophageal adenocarcinoma (EAC). However, the utility of PET/CT to assess primary tumor for endoscopic resectability and prognosis in early EAC remains unclear. We conducted a retrospective study to determine the association of PET/CT findings with histopathological tumor invasion depth and survival outcomes.MethodsEAC patients who underwent PET/CT followed by endoscopic mucosal resection (EMR) were included. Pathology on EMR and survival outcomes from a prospectively maintained database was retrieved. Two radiologists independently reviewed the PET/CT using the following parameters: detection of malignancy, fluorodeoxyglucose (FDG) uptake intensity, FDG focality, FDG eccentricity, esophageal thickness, maximal standard uptake value (SUVmax), and SUVmax ratio (lesion/liver).ResultsThere were 72 eligible patients: 42 (58.3%) had T1a lesions, and 30 (41.7%) had ≥ T1b. Only SUVmax ratio was associated with tumor invasion depth (odds ratio = 2.77, 95% confidence interval 1.26–7.73, P = 0.0075). Using a cut‐off of 1.48, the sensitivity and specificity of SUVmax ratio for identification of T1a lesions were 43.3% and 80.9%, respectively. Adjusting the SUVmax ratio to 2.14, 16.7% (5/30) of ≥ T1b patients were identified without any false‐positive cases. Multivariate analysis showed SUVmax ratio, Charlson comorbidity index, and esophagectomy were independent predictors for survival.ConclusionsSUVmax ratio (lesion/liver) is more accurate in predicting endoscopic resectability and mortality for EAC than other PET/CT parameters and appears promising as a useful adjunct to the current diagnostic work‐up.
Faculty Opinions recommendation of Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients.
Jelinek, Diane F., Greenberg, Alexandra J.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | February 21, 2013 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.717978735.793471157 Get It

How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage)
Pardanani, Animesh

Blood | February 21, 2013 | Volume: 121 | Issue: 16 | Pages: 3085-3094

10.1182/blood-2013-01-453183 | PMID 23426950 Get It

AbstractIndolent systemic mastocytosis (SM) patients have a varied clinical presentation, ranging from predominantly cutaneous symptoms to recurrent systemic symptoms (eg, flushing, palpitations, dyspepsia, diarrhea, bone pain) that can be severe and potentially life threatening (anaphylaxis). Mastocytosis patients without skin involvement pose a diagnostic challenge; a high index of suspicion is needed in those with mast cell–degranulation symptoms, including anaphylaxis following Hymenoptera stings or other triggers. Modern-era molecular and flow-cytometric diagnostic methods are very sensitive and can detect minimal involvement of bone marrow with atypical/clonal mast cells; in some cases, full diagnostic criteria for SM are not fulfilled. An important aspect of treatment is avoidance of known symptom triggers; other treatment principles include a stepwise escalation of antimediator therapies and consideration of cytoreductive therapies for those with treatment-refractory symptoms. The perioperative management of mastocytosis patients is nontrivial; a multidisciplinary preoperative assessment, adequate premedications, and close intra- and postoperative monitoring are critical. Smoldering mastocytosis is a variant with high systemic mast cell burden. While its clinical course can be variable, there is greater potential need for cytoreductive therapies (eg, interferon-alpha, cladribine) in this setting. A systematic approach to the diagnosis and treatment of indolent SM using a case-based approach of representative clinical scenarios is presented here.
A commonly carried genetic variant in the delta opioid receptor gene, OPRD1, is associated with smaller regional brain volumes: Replication in elderly and young populations
Roussotte, Florence F. , Jahanshad, Neda , Hibar, Derrek P., Sowell, Elizabeth R. , Kohannim, Omid , Barysheva, Marina, Hansell, Narelle K. , McMahon, Katie L. , Zubicaray, Greig I. de , Montgomery, Grant W. , Martin, Nicholas G. , Wright, Margaret J. , Weiner, Michael W. , Thompson, Paul M. , ADNI, the, Toga, Arthur W. , Jack, Clifford R. , ADNI, the, de Zubicaray, Greig I , Hansell, Narelle K , Martin, Nicholas G , Wright, Margaret J , Thompson, Paul M

Human Brain Mapping | February 21, 2013 | Volume: 35 | Issue: 4 | Pages: 1226-1236

10.1002/hbm.22247 | PMID 23427138 Get It

Delta opioid receptors are implicated in a variety of psychiatric and neurological disorders. These receptors play a key role in the reinforcing properties of drugs of abuse, and polymorphisms in OPRD1 (the gene encoding delta opioid receptors) are associated with drug addiction. Delta opioid receptors are also involved in protecting neurons against hypoxic and ischemic stress. Here, we first examined a large sample of 738 elderly participants with neuroimaging and genetic data from the Alzheimer's Disease Neuroimaging Initiative. We hypothesized that common variants in OPRD1 would be associated with differences in brain structure, particularly in regions relevant to addictive and neurodegenerative disorders. One very common variant (rs678849) predicted differences in regional brain volumes. We replicated the association of this single‐nucleotide polymorphism with regional tissue volumes in a large sample of young participants in the Queensland Twin Imaging study. Although the same allele was associated with reduced volumes in both cohorts, the brain regions affected differed between the two samples. In healthy elderly, exploratory analyses suggested that the genotype associated with reduced brain volumes in both cohorts may also predict cerebrospinal fluid levels of neurodegenerative biomarkers, but this requires confirmation. If opiate receptor genetic variants are related to individual differences in brain structure, genotyping of these variants may be helpful when designing clinical trials targeting delta opioid receptors to treat neurological disorders. Hum Brain Mapp 35:1226–1236, 2014 . © 2013 Wiley Periodicals, Inc.